Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia

J V Jovanovic, J Score, K Waghorn, D Cilloni, E Gottardi, G Metzgeroth, P Erben, H Popp, C Walz, A Hochhaus, C Roche-Lestienne, C Preudhomme, E Solomon, J Apperley, M Rondoni, E Ottaviani, G Martinelli, F Brito-Babapulle, G Saglio, R HehlmannN C P Cross, A Reiter, D Grimwade

Research output: Contribution to journal › Article › peer-review

191 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia'. Together they form a unique fingerprint.

Biochemistry, Genetics and Molecular Biology